AstraZeneca plc (LON:AZN) PT Set at GBX 4,200 by J P Morgan Chase & Co
AstraZeneca plc (LON:AZN) received a GBX 4,200 ($54.69) target price from analysts at J P Morgan Chase & Co in a note issued to investors on Wednesday. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. J P Morgan Chase & Co’s price target would indicate a potential downside of 5.12% from the company’s previous close.
AZN has been the topic of a number of other reports. Morgan Stanley restated an “overweight” rating and set a GBX 5,600 ($72.93) target price on shares of AstraZeneca plc in a report on Friday, June 23rd. Deutsche Bank AG restated a “buy” rating on shares of AstraZeneca plc in a report on Monday, May 22nd. Shore Capital restated a “sell” rating on shares of AstraZeneca plc in a report on Thursday, May 4th. Barclays PLC restated an “overweight” rating and set a GBX 6,000 ($78.14) target price on shares of AstraZeneca plc in a report on Monday, June 5th. Finally, Liberum Capital restated a “buy” rating and set a GBX 5,500 ($71.62) target price on shares of AstraZeneca plc in a report on Wednesday, June 14th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of GBX 4,932.67 ($64.24).
Shares of AstraZeneca plc (LON:AZN) opened at 4426.50 on Wednesday. The company’s 50 day moving average is GBX 4,972.77 and its 200 day moving average is GBX 4,859.70. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The company’s market capitalization is GBX 56.04 billion.
In other news, insider Nazneen Rahman acquired 39 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The stock was acquired at an average price of GBX 4,370 ($56.91) per share, with a total value of £1,704.30 ($2,219.43).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.